Abstract 4184: Tumor and risk factor characteristics among breast cancer patients from different geographic regions in Peru
Valentina A. Zavala(San Francisco General Hospital), Laura Fejerman(University of California, San Francisco), JE Abugattas(Instituto Nacional de Enfermedades Neoplásicas), Tatiana Vidaurre(The University of Texas MD Anderson Cancer Center), Sikai Song(San Francisco General Hospital), Henry Gómez(National Cancer Center), Renzo Meza Florez(Instituto Nacional de Enfermedades Neoplásicas), Jeannie Navarro Vásquez(Instituto Nacional de Enfermedades Neoplásicas), Sandro Casavilca‐Zambrano(Institute for Anthropological Research), Hugo Fuentes(Instituto Nacional de Enfermedades Neoplásicas), Claudia Monge(Instituto Nacional de Enfermedades Neoplásicas), Daniel Cherry(University of San Diego), Lizeth I. Tamayo(University of Illinois Chicago), Mónica Calderón(Instituto Nacional de Enfermedades Neoplásicas), Katie M. Marker(Berkeley College)
Cited by 1
Related Papers
Adjuvant Exemestane with Ovarian Suppression in Premenopausal Breast Cancer
|New England Journal of Medicine|2014|751
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
|New England Journal of Medicine|2018|684
High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial
|The Lancet|2009|665
Ixabepilone Plus Capecitabine for Metastatic Breast Cancer Progressing After Anthracycline and Taxane Treatment
|Journal of Clinical Oncology|2007|483